Question: How did the visitors react to Medical IP's booth exhibition and demonstration during RSNA 2022, and what technology or service particularly received attention?
Answer: Medical IP introduced various product lineups through RSNA 2022.
While all technologies and products received attention, the RSNA participants who visited the booth especially showed interest in our metaverse implementation of medical image-based anatomical structures and 3D quantitative analysis technology of X-ray images.
Q: Has the company made any changes to its booth compared to last year?
A: Unlike last year, we set up two booths instead of one during RSNA 2022.
Mainly, we planned a booth focusing on segmenting medical images through AI technology and implementing them into digital twins, a virtual model designed to accurately reflect a physical object, to analyze them, or implement them in the virtual space.
The booth showcased MEDIP PRO (a medical image AI segmentation and analysis and digital twin implementation software), MEDIP PRO AR (augmented reality (AR) solution for surgical navigation), DeepCatch (CT-based automatic body composition analysis software), TiSepX (X-ray 3D quantitative analysis platform), and MDBOX (an anatomical digital twin-based medical metaverse platform).
In the other booth, the company presented ANATDEL, a medical 3D printing solution that expanded Medical IP's medical AI technology and digital twin implementation technology to the 3D printing area.
Q: Unlike other Korean AI medical device companies, Medical IP emphasizes keywords such as digital twin and metaverse in the medical field. How is the company's business direction different from other diagnosis-assisted AI development companies?
A: Many medical AI companies based on medical imaging are developing diagnosis-assisted AI for specific target diseases.
AI technology, which adds an objective basis to the knowledge and know-how of physicians in identifying the presence or absence of lesions that are difficult to discern with the naked eye, is often used in the "diagnosis" stage of patients.
However, Medical IP converges AI-based medical image analysis technology with various advanced technologies to focus on expanding to a wider medical field.
We go beyond quantifying and analyzing the patient's organs and lesions through medical images and implement it as a real-life digital twin to utilize the internal information of the human body in the metaverse.
This technology can be used not only in diagnosis but throughout the treatment process, ensuring the safety of doctors and patients.
For example, MDBOX, which was developed to utilize the digital twin of 3,000 anatomical structures in the metaverse, is a product that can be used for anatomy practice training for pre-medical staff to replace cadavers for dissection.
Q: How important is AI segmentation technology in the field of radiology?
A: AI segmentation technology is the basis for realizing medical image AI analysis.
Anatomical structures contained in medical image data must be accurately segmented to enable quantitative analysis of each region.
In the past, radiologists performed the segmentation work directly. However, there were many limitations, such as time and cost problems, accuracy, and difficulties in big data analysis.
Medical IP has developed an AI technology that has increased the efficiency and accuracy of this segmentation work.
Q: How much do you think Medical IP's technological prowess is compared to foreign or domestic medical AI companies?
A: Medical IP's technologies, such as AI segmentation and analysis of medical images, implementation of digital twins based on medical images, and 3D analysis of 2D images, are differentiated from other domestic medical AI companies.
It is difficult to simply say that we have a comparative advantage over other companies. But through various achievements, Medical IP has proven its technological competitiveness and excellence.
Also, thorough verification is essential for technologies and products used in the medical field, and they must go through a performance evaluation process using clinical data.
On this note, Medical IP proved its achievements by publishing research papers inSCIE journals.
The company has published papers in 57 SCIE journals since 2020, including clinical papers published in the Radiology and Journal of Thoracic Oncology, which is renowned in the healthcare and medical field.
Q: What is Medical IP's goal for attending RSNA 2022?
A: RSNA is a convention where tens of thousands of radiologists and medical industry officials from all over the world discuss the present and future of radiology and seek technological innovation and development of the medical industry.
Medical IP focuses on improving the value of medical image data and solving unmet needs in the medical field by utilizing the company's technology throughout the entire medical cycle.
Therefore, we hope that this conference will serve as an opportunity for medical professionals from around the world to discover and introduce our solutions that can enhance safety, efficiency, and convenience.
From the company's point of view, we expect to see new business opportunities and lead development in the radiology industry by utilizing the company's cutting-edge technology.
Q: What new areas of research or business does the company wants to advance in the future?
A: I believe that research through the combination of heterogeneous data will become more active in realizing prevention and prediction-oriented precision medicine.
As a result, the company has secured technology that can quantify medical images such as CT and X-ray, and can be combined with various medical data such as blood tests and genome data.
This will allow more accurate identification of the patient's condition, which will help predict the possibility of onset.
Also, the company expects its quantification solution will enable active product development in the pharmaceutical industry as it enables prediction of drug response.